| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
|
J Clin Oncol
|
2006
|
5.02
|
|
2
|
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.
|
Nat Med
|
2010
|
2.92
|
|
3
|
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
|
Blood
|
2010
|
2.31
|
|
4
|
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.
|
Mol Ther
|
2013
|
1.89
|
|
5
|
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
|
Cancer Immunol Immunother
|
2007
|
1.86
|
|
6
|
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells.
|
Cytotherapy
|
2013
|
1.43
|
|
7
|
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
|
J Immunol
|
2003
|
1.41
|
|
8
|
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
|
Trends Mol Med
|
2012
|
1.32
|
|
9
|
Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.
|
J Immunol
|
2007
|
1.15
|
|
10
|
Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer.
|
J Immunol
|
2008
|
1.15
|
|
11
|
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
|
Cancer Res
|
2009
|
1.10
|
|
12
|
T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing.
|
Trends Mol Med
|
2010
|
1.07
|
|
13
|
Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy.
|
Cytometry A
|
2008
|
1.04
|
|
14
|
Genetic engineering of T cell specificity for immunotherapy of cancer.
|
Hum Immunol
|
2003
|
1.04
|
|
15
|
Development of adoptive cell therapy for cancer: a clinical perspective.
|
Hum Gene Ther
|
2010
|
1.03
|
|
16
|
Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
|
Cancer Immunol Immunother
|
2010
|
1.03
|
|
17
|
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.
|
J Immunol
|
2005
|
1.01
|
|
18
|
T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.
|
Expert Opin Biol Ther
|
2010
|
0.99
|
|
19
|
Long wavelength fluorophores and cell-by-cell correction for autofluorescence significantly improves the accuracy of flow cytometric energy transfer measurements on a dual-laser benchtop flow cytometer.
|
Cytometry
|
2002
|
0.98
|
|
20
|
Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
|
Cancer Gene Ther
|
2002
|
0.94
|
|
21
|
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
|
Clin Dev Immunol
|
2012
|
0.94
|
|
22
|
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs.
|
J Immunol
|
2010
|
0.92
|
|
23
|
Chimeric antigen receptors for T-cell based therapy.
|
Methods Mol Biol
|
2012
|
0.92
|
|
24
|
CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10.
|
J Immunol
|
2006
|
0.89
|
|
25
|
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu.
|
Front Immunol
|
2013
|
0.87
|
|
26
|
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
|
Hum Gene Ther Methods
|
2014
|
0.87
|
|
27
|
T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.
|
Int Immunol
|
2006
|
0.85
|
|
28
|
An oncolytic adenovirus redirected with a tumor-specific T-cell receptor.
|
Cancer Res
|
2007
|
0.85
|
|
29
|
T-cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR:ζ, a candidate transgene for TCR gene therapy.
|
Eur J Immunol
|
2011
|
0.82
|
|
30
|
TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
|
Mol Immunol
|
2010
|
0.81
|
|
31
|
Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.
|
J Gene Med
|
2007
|
0.80
|
|
32
|
Flexible and sensitive method to functionally validate tumor-specific receptors via activation of NFAT.
|
J Immunol Methods
|
2003
|
0.79
|
|
33
|
T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
|
Hum Gene Ther
|
2011
|
0.79
|
|
34
|
T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
|
J Immunol Methods
|
2010
|
0.79
|
|
35
|
Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells.
|
Hum Gene Ther Methods
|
2012
|
0.78
|
|
36
|
An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.
|
Front Immunol
|
2013
|
0.78
|
|
37
|
mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells.
|
Thromb Haemost
|
2010
|
0.77
|
|
38
|
TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs.
|
Eur J Immunol
|
2013
|
0.77
|
|
39
|
Adoptive transfer of T-cell immunity: gene transfer with MHC-restricted receptors.
|
Trends Immunol
|
2002
|
0.76
|
|
40
|
Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors.
|
J Immunother
|
2009
|
0.75
|
|
41
|
Genetically modified T lymphocytes: more than just direct effectors.
|
Immunotherapy
|
2013
|
0.75
|